About Sunflower Therapeutics
Sunflower Therapeutics is a private company based in Hingham, Massachusetts, incorporated in 2022 in Delaware. It has reported $2,640,000 raised in two offerings on Form D since October 2022. Its chief executive is Kerry Love.
Funding Rounds (SEC Form D)
| First sale | Filed with SEC | Amount sold | Investors | Avg. check | Terms | Filing |
|---|---|---|---|---|---|---|
| May 13, 2024 | May 24, 2024 | $2,030,000of $3.0M target | 2 | $1.0M | Options, Securities on exercise, Simple agreement for future equityRule 506(b) | Form D ↗ |
| Sep 28, 2022 | Oct 14, 2022 | $610,000of $1.5M target | 8 | $76,250 | Equity, OptionsRule 506(b) | Form D ↗ |
| Total, two offerings | $2,640,000 | |||||
First sale is the date the first investor in the offering committed to invest. Companies must file Form D within 15 days of that date, so filing dates run later.
Leadership Team
Executive officers and directors listed on Sunflower Therapeutics's Form D filed May 24, 2024.
LW
Larry Weiner
Director
JL
J. Christopher Love
Director
MJ
Maik Jornitz
Director
KL
Kerry Love
Chief Executive Officer and director
Earlier filings also listed Kathryn Golden (director, last listed Oct 2022).